Arna Pharma
Arna Pharma is a specialty pharmaceutical company that develops and manufactures mannitol-based Dry Powder Inhalation products (Bronchitol®, Aridol®/Osmohale®) for cystic fibrosis and respiratory care, distributed across 23+ global markets and manufactured at a GMP-certified Sydney facility.
- Company typePrivate
- Founded2021
- HeadquartersSydney, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Arna Pharma does
Arna Pharma is a privately held, vertically integrated specialty pharmaceutical company founded in 2021 with global headquarters in Dublin, Ireland, and operations spanning Australia, the United States, the United Kingdom, and India. The company develops and manufactures two proprietary Dry Powder Inhalation (DPI) products — Bronchitol® (mannitol for cystic fibrosis treatment) and Aridol®/Osmohale® (mannitol for bronchial challenge diagnostics) — at its GMP-certified Sydney facility, which holds US FDA, TGA, and EU-GMP approvals and distributes these products across more than 23 major pharmaceutical markets globally. Arna Pharma serves rare disease patients (cystic fibrosis, ocular cystinosis) and the broader respiratory care market, while also operating a Contract Development and Manufacturing Organization (CDMO) division that provides formulation development, scale-up, and commercial manufacturing services to third-party pharmaceutical companies in niche dosage forms including oral solids, injectables, ophthalmic, topicals, and oral dispersible films.
The company generates revenue through three streams: sales of proprietary branded pharmaceutical products, CDMO service contracts and manufacturing fees, and licensing/royalty arrangements for 505(b)(2) medicines and specialized generics channeled through its joint venture with Slate Run Pharmaceuticals, which was finalized in May 2026 and launched Aridol® in the U.S. market as its first co-developed product. Its go-to-market combines enterprise field sales targeting healthcare providers and institutional buyers, distribution partnerships with global pharmaceutical wholesalers including Cardinal Health and Etico, and the recently established U.S. JV channel. The company employs 136 professionals globally across R&D, manufacturing, regulatory affairs, marketing, and distribution, with a research center in Hyderabad supporting advanced formulation development and senior leadership bringing 20-36 years of pharmaceutical experience from companies including Pfizer, Aspen Pharmacare, Aurobindo, Laurus Labs, and Indian Oil.
Arna Pharma firmographics
Firmographics- Name
- Arna Pharma
- Legal name
- Arna Pharma Inc.
- Website
- https://arnapharma.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Arna Pharma is a specialty pharmaceutical company that develops and manufactures mannitol-based Dry Powder Inhalation products (Bronchitol®, Aridol®/Osmohale®) for cystic fibrosis and respiratory care, distributed across 23+ global markets and manufactured at a GMP-certified Sydney facility.
- Ownership category
- akta.pro rank
Arna Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
- akta.pro secondary industries
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Arna Pharma is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices7 records
Markets served
Arna Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Proprietary Pharmaceutical Products: Sales of proprietary branded pharmaceutical products including respiratory therapies (Bronchitol, Aridol) marketed in 23+ global markets. Focus on rare diseases like Cystic Fibrosis and niche therapeutic segments.
- CDMO Services: Contract Development and Manufacturing services offered to pharmaceutical companies including product formulation, scale-up, and commercial manufacturing. Revenue generated through service contracts and manufacturing fees.
- 505(b)(2) and Specialized Generics: Development and commercialization of 505(b)(2) medicines and specialized generic products through the joint venture with Slate Run Pharmaceuticals, targeting high-value therapeutic segments in the U.S. market.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
Arna Pharma product offering
Product offeringCore offering
Arna Pharma is a fully integrated specialty pharmaceutical company that develops, manufactures, and commercializes niche respiratory pharmaceutical products, including Dry Powder Inhalation therapies Bronchitol (mannitol for cystic fibrosis) and Aridol/Osmohale (mannitol bronchial challenge diagnostic). The company also operates a Contract Development and Manufacturing Organization (CDMO) offering formulation development, scale-up, and commercial manufacturing services to other pharmaceutical companies. Manufacturing is performed at a GMP-certified facility in Sydney, Australia approved by US FDA, TGA, and EU-GMP.
Product overview
Arna Pharma is a fully integrated pharmaceutical company offering end-to-end capabilities from formulation development and manufacturing to global marketing and commercialization. The company's core proprietary products include two Dry Powder for Inhalation products—Bronchitol® (mannitol for treating cystic fibrosis) and Aridol®/Osmohale® (bronchial challenge diagnostic)—both manufactured at their GMP-certified Sydney facility and marketed across 23+ global markets. Beyond proprietary products, Arna Pharma operates a Contract Development and Manufacturing Organization (CDMO) division offering formulation development, scale-up, and commercial manufacturing services to pharmaceutical companies. The portfolio emphasizes niche dosage forms including oral solids, injectables, ophthalmic, and topical formulations, with therapeutic focus on respiratory diseases, rare genetic conditions (including cystic fibrosis and ocular cystinosis), cardiovascular disorders, neurology, infectious diseases, and oncology.
Differentiator
Problem solved
Functional benefit
Products and services
- Bronchitol Mannitol inhalation powder (40mg capsules for dry powder oral inhalation) is a prescription osmotic agent approved for the treatment of cystic fibrosis in selected patients. It works by drawing water into the airways to thin and clear mucus, improving lung function and reducing respiratory infection risk.
- Aridol / Osmohale Mannitol inhalation powder for bronchial challenge testing, a diagnostic agent used to identify bronchial hyperresponsiveness, a hallmark of asthma and other airway disorders. Available as a standardized test kit containing pre-filled mannitol capsules and a handheld dry powder inhaler.
- CDMO Services (Contract Development and Manufacturing) Contract Development and Manufacturing Organization services for pharmaceutical companies, including product formulation development, scale-up, technology transfer, life cycle management, and commercial manufacturing across oral solids, injectables, ophthalmic, topicals, and specialized delivery systems including Dry Powder Inhalation and oral dispersible films.
Quantifiable outcome
- Products marketed in 23+ major pharma markets globally
- +1 more outcomes
Companies that use Arna Pharma
Customer profileSegments4 records
Ideal customer profiles3 records
Arna Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Arna Pharma partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Slate Run PharmaceuticalscoreJoint venture finalized May 2026 to create a scaled-up U.S.-based specialty pharmaceutical company. Combines Arna Pharma's development capabilities with Slate Run's established U.S. commercial, regulatory, and supply chain infrastructure. Focus on branded products, 505(b)(2) medicines, and specialized generics. First co-developed product Aridol launched in U.S. market on May 14, 2026.
- Slate Run PharmaceuticalscoreMOU signed February 2026 to form U.S.-based specialty pharmaceutical joint venture. Partnership aims to scale branded and specialized products across U.S. market while expanding patient access to specialty medications.
- Pharmaceutical ManufacturersminorSeeking strategic alliances with pharmaceutical manufacturers for collaborative product development and manufacturing partnerships.
- Research OrganizationsminorActively seeking partnerships with research organizations to drive innovation in pharmaceutical development.
- DistributorsminorPartner logo displayed on company website indicating distribution partnerships for global pharmaceutical product distribution.
- CDMO ClientsminorOffers contract development and manufacturing services to pharmaceutical companies seeking reliable, high-quality partners for product formulation, scale-up, and commercial manufacturing.
Scale indicators4 records
Recent moves6 records
Expansion highlights7 records
Arna Pharma competitors and assessment
Company assessmentDirect peers
- Recipharm: Recipharm is a global CDMO offering formulation development and commercial manufacturing across multiple dosage forms including inhalation. Directly comparable to Arna Pharma's CDMO division for outsourced pharmaceutical manufacturing services.
- Hovione: Hovione is a global CDMO specializing in inhalation and dry powder formulations, with DPI capabilities and GMP facilities analogous to Arna Pharma's manufacturing operations. It is the most direct CDMO peer given overlapping DPI expertise and pharmaceutical manufacturing scope.
- Chiesi Farmaceutici: Chiesi is a privately-held specialty pharmaceutical company with a major respiratory franchise and rare disease portfolio, including cystic fibrosis therapies. Direct competitor in respiratory and a key benchmark for Arna's commercial strategy in pulmonology.
- Zambon: Zambon is a privately-held specialty pharmaceutical company with respiratory, rare disease, and CDMO activities through its Zambon Pharma and Z-Cube ventures. Comparable to Arna in combining proprietary specialty respiratory products with contract manufacturing.
Broad incumbents
- Aspen Pharmacare: Aspen is a major South African-headquartered specialty pharmaceutical company with respiratory and rare disease portfolios plus global manufacturing. Multiple Arna leaders worked at Aspen, and its respiratory franchise provides a relevant large-scale benchmark.
- Laurus Labs: Laurus Labs is an Indian pharmaceutical manufacturer with API and formulation capabilities including CDMO services. Comparable through formulation development and CDMO offerings; shares talent lineage with Arna's VP R&D.
- Aurobindo Pharma: Aurobindo is a large Indian generic and specialty pharmaceutical manufacturer with broad formulation capabilities and CDMO services. Overlaps with Arna Pharma's CDMO operations and shares talent lineage (VP R&D previously at Aurobindo).
- Catalent: Catalent is a large global CDMO with extensive inhalation and soft-mist formulation capabilities serving pharmaceutical clients. Overlaps with Arna Pharma's CDMO services but operates at much larger scale across many dosage forms and geographies.
Others
- Pharmaxis Ltd: Pharmaxis is the Australian specialty pharma company from which Arna Pharma's mannitol-based Bronchitol and Aridol products were inherited. Relevant as the predecessor entity and for understanding product history, regulatory filings, and IP origins.
Emerging players
- Verona Pharma: Verona Pharma is a late-stage respiratory biopharmaceutical company developing inhaled therapies for COPD and other respiratory diseases. Comparable as a respiratory-focused specialty pharma building commercial capability through specialized inhalation products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Arna Pharma social profiles
Digital presenceArna Pharma compliance and trust
Trust signalCompliance4 records
Arna Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arna Pharma leadership team
Management profileNumber of profiles
Profiles7 records
Arna Pharma subsidiaries and ownership
Company hierarchySubsidiaries7 records
Arna Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arna Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arna Pharma
What does Arna Pharma do?
Arna Pharma is a fully integrated specialty pharmaceutical company that develops, manufactures, and commercializes niche respiratory pharmaceutical products, including Dry Powder Inhalation therapies Bronchitol (mannitol for cystic fibrosis) and Aridol/Osmohale (mannitol bronchial challenge diagnostic). The company also operates a Contract Development and Manufacturing Organization (CDMO) offering formulation development, scale-up, and commercial manufacturing services to other pharmaceutical companies. Manufacturing is performed at a GMP-certified facility in Sydney, Australia approved by US FDA, TGA, and EU-GMP.
Is Arna Pharma a public or private company?
Arna Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Arna Pharma founded?
Arna Pharma was founded in 2021. It employs 11 to 50 people.
Where is Arna Pharma based?
Arna Pharma is headquartered in Sydney, Australia, in the Oceania region.
How does Arna Pharma make money?
Three revenue lines are on record. Proprietary Pharmaceutical Products are the primary driver. The others are CDMO Services and 505(b)(2) and Specialized Generics.
Who are Arna Pharma's main competitors?
Direct peers on record are Recipharm, Hovione, Chiesi Farmaceutici and Zambon. Broad incumbents are Aspen Pharmacare, Laurus Labs, Aurobindo Pharma and Catalent. Pharmaxis Ltd is listed as an others. Verona Pharma is listed as an emerging player.
Does Arna Pharma have an API?
No public API is recorded for Arna Pharma.
What industry is Arna Pharma in?
Arna Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals, with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.